Author:Bio-four Introduction On March 26, 2025, the TROP2 dual payload ADC drug KH815 developed by Kanghong Biotech received clinical trial approval from the Australian HREC and obtained clinical approval in China on April 16, 2025, making it the world’s first dual payload ADC approved for clinical use.During this year’s AACR conference and related patents made … Read more
The medical community welcomes a new “weapon” against cancer, as a domestic innovative drug demonstrates outstanding performance in the treatment of lung cancer and breast cancer, bringing new hope to advanced patients.At the 2025 European Society for Medical Oncology (ESMO) annual meeting, a domestically developed innovative antibody-drug conjugate—Lukangsatuzumab (Sac-TMT, Jiatai Lai®)—announced multiple Phase III clinical … Read more
Introduction Breast cancer is one of the most common malignant tumors among women worldwide and is also a leading cause of cancer-related deaths. According to the data released in the “2022 Global Cancer Statistics Report”, there were approximately 20 million new cancer cases globally, with women accounting for 9.7 million, and breast cancer accounting for … Read more
Click the blue text to follow us With the advent of biomarker-guided personalized targeted therapies and immune checkpoint inhibitors, the treatment of non-small cell lung cancer (NSCLC) continues to undergo transformation. Recently, antibody-drug conjugates (ADCs) have brought revolutionary new hope, such as trastuzumab-deruxtecan (T-DXd) being used for previously treated HER2 (ERBB2) mutated advanced NSCLC, which … Read more
Breast cancer is the leading cause of death among women in China and worldwide. When breast cancer spreads to other parts of the body, the prognosis is poor. Currently, there is no treatment for metastatic breast cancer. Antibody-drug conjugates (ADCs) are a new type of anticancer drug consisting of antibodies, linkers, and cytotoxic agents [1]. … Read more
The ASCENT-04 study is a global, multicenter, randomized, open-label phase III clinical trial designed to evaluate the efficacy and safety of the TROP2-targeted antibody-drug conjugate (ADC) sacituzumab govitecan (SG) combined with the PD-1 inhibitor pembrolizumab (Keytruda, K drug) compared to chemotherapy combined with K drug in first-line treatment of PD-L1 positive (CPS≥10) metastatic triple-negative breast … Read more
Abstract:TROP2 (Trophoblast Cell Surface Antigen 2) is a tumor-associated antigen that is highly expressed in various solid tumors and has become a popular target for antibody-drug conjugates (ADCs). This article systematically introduces the biological characteristics of TROP2 and its expression profile in tumors, focusing on the molecular design, mechanism of action, and clinical efficacy of … Read more
The Concept and Development History of ADC The treatment of tumors has always undergone a continuous transformation from theory to application, breaking and transforming again. As early as a century ago, scholars proposed the concept of antibody-drug conjugates (ADCs), vividly calling them “magic bullets,” aimed at targeting specific antigens that may exist on the surface … Read more
Antibody-drug conjugates (ADC), also known as “magic bullets,” use monoclonal antibodies (Antibody) to deliver small molecule drugs (Drug) directly to tumor cells expressing specific antigens through a linker (Conjugate). In recent years, ADC drugs have rewritten the treatment guidelines for blood cancers, breast cancer, ovarian cancer, and lung cancer, providing patients with significantly improved clinical … Read more